{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:26:23Z","timestamp":1769603183982,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12881-018-0703-9","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T03:29:35Z","timestamp":1539746975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Yi","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0586-5877","authenticated-orcid":false,"given":"Lijie","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"issue":"11","key":"703_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"703_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"703_CR3","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/bjc.2011.383","volume":"105","author":"Z Kote-Jarai","year":"2011","unstructured":"Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O\u2019Brien L, Sawyer E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230\u20134.","journal-title":"Br J Cancer"},{"issue":"12","key":"703_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/jnci\/djm005","volume":"99","author":"L Tryggvadottir","year":"2007","unstructured":"Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(12):929\u201335.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"703_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","volume":"99","author":"SA Narod","year":"2008","unstructured":"Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008;99(2):371\u20134.","journal-title":"Br J Cancer"},{"issue":"1","key":"703_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"J Morales","year":"2014","unstructured":"Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J, Boothman DA. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24(1):15\u201328.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"6","key":"703_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al. Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"703_CR8","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/cncr.29995","volume":"122","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844\u201352.","journal-title":"Cancer"},{"issue":"18","key":"703_CR9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, et al. DNA-repair defects and Olaparib in metastatic prostate Cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med"},{"key":"703_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2147\/DDDT.S110264","volume":"11","author":"F De Felice","year":"2017","unstructured":"De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C. Defective DNA repair mechanisms in prostate cancer: impact of olaparib. Drug Des Devel Ther. 2017;11:547\u201352.","journal-title":"Drug Des Devel Ther"},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/0008-5472.CAN-06-4202","volume":"67","author":"J Jiao","year":"2007","unstructured":"Jiao J, Wang S, Qiao R, et al. Murine cell linesderived fromPten null prostate cancer showthe critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 2007;67:6083\u201391.","journal-title":"Cancer Res"},{"key":"703_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575\u201386.","journal-title":"Cancer Cell"},{"key":"703_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","volume":"36","author":"M Hussain","year":"2018","unstructured":"Hussain M, Daignault-Newton S, Twardowski PW, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol. 2018;36:991\u20139.","journal-title":"J Clin Oncol"},{"key":"703_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","volume":"74","author":"ES Antonarakis","year":"2018","unstructured":"Antonarakis ES, Lu C, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74:218\u201325.","journal-title":"Eur Urol"},{"issue":"15","key":"703_CR15","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","volume":"26","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Achatz MI, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157\u201365.","journal-title":"Oncogene"},{"key":"703_CR16","doi-asserted-by":"crossref","unstructured":"Schlomm T, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011\u201325.","DOI":"10.1016\/j.cell.2015.10.025"},{"issue":"2","key":"703_CR17","doi-asserted-by":"publisher","first-page":"e1291397","DOI":"10.1080\/23723556.2017.1291397","volume":"4","author":"Kristine M. Wadosky","year":"2017","unstructured":"Wadosky KM, Ellis L, et al. Evasion of targeted cancer therapy through stemcell-like reprogramming. Mol Cell Oncol. 2017;4(2):2372\u20133556.","journal-title":"Molecular & Cellular Oncology"},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1038\/ncomms7377","volume":"6","author":"MJ Niederst","year":"2015","unstructured":"Niederst MJ, Sequist LV, Poirier JT, Mermel CH, et al. Rb loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.","journal-title":"Nat Commun"},{"issue":"9","key":"703_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley D, et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 2017;7(9):999\u20131005.","journal-title":"Cancer Discov"},{"issue":"9","key":"703_CR20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall J, et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7(9):1006\u201317.","journal-title":"Cancer Discov"},{"issue":"11","key":"703_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","volume":"19","author":"CJ Lord","year":"2013","unstructured":"Lord CJ, Ashworth A, et al. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19(11):1381\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"703_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.maturitas.2015.01.015","volume":"81","author":"S Tangutoori","year":"2015","unstructured":"Tangutoori S, Baldwin P, Sridhar S, et al. PARP inhibitors: a new era of targeted therapy. Maturitas. 2015;81(1):5\u20139.","journal-title":"Maturitas"},{"key":"703_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14728214.2018.1459563","volume":"23","author":"ES Christenson","year":"2018","unstructured":"Christenson ES, Antonarakis ES, et al. PARP inhibitors for homologous recombination deficient prostate cancer. Expert Opin Emerg Drugs. 2018;23:123\u201333.","journal-title":"Expert Opin Emerg Drugs"},{"key":"703_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fphar.2013.00018","volume":"4","author":"A Montoni","year":"2013","unstructured":"Montoni A, Robu M, Pouliot E, Shah GM, et al. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol. 2013;4:18.","journal-title":"Front Pharmacol"},{"issue":"6","key":"703_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nsmb.1831","volume":"17","author":"P Bouwman","year":"2010","unstructured":"Bouwman P, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688\u201395.","journal-title":"Nat Struct Mol Biol"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-018-0703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12881-018-0703-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-018-0703-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:15:25Z","timestamp":1571253325000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/s12881-018-0703-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1186\/s12881-018-0703-9","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"12 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The publication of this manuscript has been reviewed and approved by the People\u2019s Hospital of Liaoning Province institutional review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and his family have consent to publish the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"185"}}